A Delhi High Court ruling favors Natco Pharma against Roche's rare disease drug. Natco can now launch generic risdiplam, used for spinal mu...

The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...

Recent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...

The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart cond...

Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche ...

The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...

Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...

Health groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monop...